Todd Strategy Group
Todd Strategy Group filed a Q3 report for Eli Lilly and Company on October 20, 2026, reporting $80,000 in lobbying income.
Lobbying for Eli Lilly and Company · American pharmaceutical company.
-
NICHOLAS UEHLECKEPreviously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
-
NICOLAS MAGALLANESPreviously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander
-
ERIC BERGRENPreviously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
-
KATHERINE FLEMING COTTONPreviously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
-
PAUL EDATTELPreviously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
-
DANIEL M TODDPreviously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
Health insurance accessibility. Artificial Intelligence in health care.
Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access. CMS National Coverage Determination on Alzheimer's disease. Implementation of the Inflation Reduction Act.
Drug pricing, coverage, value, access and quality. Prescription drug approval. Drug importation. 340 B. Intellectual property. Pharmaceutical supply chain issues and shortages. Transparency. Issues related to intellectual property protection and market access within current trade negotiations.